A composite subunit vaccine confers full protection against Buruli ulcer disease in the mouse footpad model of Mycobacterium ulcerans infection.

Buruli ulcer (BU) disease, a neglected necrotizing tropical skin infection caused by Mycobacterium ulcerans, is the third most common mycobacterial disease after tuberculosis and leprosy. Infections mostly occur in remote, rural areas of Central and West Africa, but also in Australia, Japan and Papu...

Full description

Bibliographic Details
Published in:	PLoS Neglected Tropical Diseases
Main Authors:	Justice Kofi Boakye-Appiah, Andy C Tran, Matthew J Paul, Peter Hart, Richard O Phillips, Thomas S Harrison, Mark Wansbrough-Jones, Rajko Reljic
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2025-02-01
Online Access:	https://doi.org/10.1371/journal.pntd.0012710

Similar Items

Genetic diversity of PCR-positive, culture-negative and culture-positive Mycobacterium ulcerans isolated from Buruli ulcer patients in Ghana.
by: Heather Williamson, et al.
Published: (2014-01-01)

Mycobacterium ulcerans persistence at a village water source of Buruli ulcer patients.
by: Martin W Bratschi, et al.
Published: (2014-03-01)

Repurposing of statins for Buruli Ulcer treatment: antimicrobial activity against Mycobacterium ulcerans
by: Juan Dominguez, et al.
Published: (2023-09-01)

Spatial Distribution of Mycobacterium ulcerans in Buruli Ulcer Lesions: Implications for Laboratory Diagnosis.
by: Marie-Thérèse Ruf, et al.
Published: (2016-06-01)

Volatile organic compound detection of Buruli ulcer disease: Headspace analysis of Mycobacterium ulcerans and used gauzes of Buruli-compatible ulcers.
by: Stan F J Chudy, et al.
Published: (2024-09-01)

Evidences of the Low Implication of Mosquitoes in the Transmission of Mycobacterium ulcerans, the Causative Agent of Buruli Ulcer
by: Rousseau Djouaka, et al.
Published: (2017-01-01)

Experimental infection of ringtail possums (Pseudocheirus peregrinus) with Mycobacterium ulcerans, the agent of Buruli ulcer
by: Kim R. Blasdell, et al.
Published: (2024-10-01)

PPE Barcoding Identifies Biclonal Mycobacterium ulcerans Buruli Ulcer, Côte d’Ivoire
by: B. G. O. Tchan, et al.
Published: (2023-06-01)

Analysis of Mycobacterium ulcerans-specific T-cell cytokines for diagnosis of Buruli ulcer disease and as potential indicator for disease progression.
by: Norman Nausch, et al.
Published: (2017-02-01)

Mycobacterium ulcerans not detected by PCR on human skin in Buruli ulcer endemic areas of south eastern Australia.
by: Anita Velink, et al.
Published: (2023-10-01)

Mosquitoes as Vectors of Mycobacterium ulcerans Based on Analysis of Notifications of Alphavirus Infection and Buruli Ulcer, Victoria, Australia
by: Andrew H. Buultjens, et al.
Published: (2024-09-01)

Experimental infection of the pig with Mycobacterium ulcerans: a novel model for studying the pathogenesis of Buruli ulcer disease.
by: Miriam Bolz, et al.
Published: (2014-07-01)

Overexpression of a Mycobacterium ulcerans Ag85B-EsxH Fusion Protein in Recombinant BCG Improves Experimental Buruli Ulcer Vaccine Efficacy.
by: Bryan E Hart, et al.
Published: (2016-12-01)

Buruli ulcer surveillance in south-eastern Australian possums: Infection status, lesion mapping and internal distribution of Mycobacterium ulcerans.
by: Emma C Hobbs, et al.
Published: (2024-11-01)

Delays in Patient Presentation and Diagnosis for Buruli Ulcer (<i>Mycobacterium ulcerans</i> Infection) in Victoria, Australia, 2011–2017
by: Shaun P. Coutts, et al.
Published: (2019-07-01)

Clearance of viable Mycobacterium ulcerans from Buruli ulcer lesions during antibiotic treatment as determined by combined 16S rRNA reverse transcriptase /IS 2404 qPCR assay.
by: Mabel Sarpong-Duah, et al.
Published: (2017-07-01)

Mycobacterium ulcerans disease
by: Tjip S. van der Werf, et al.

A refined low-dose murine model of Mycobacterium ulcerans infection to assess integrated immune networks in Buruli ulcer pathogenesis
by: Stephen Muhi, et al.
Published: (2025-09-01)

A human model of Buruli ulcer: The case for controlled human infection and considerations for selecting a Mycobacterium ulcerans challenge strain.
by: Stephen Muhi, et al.
Published: (2023-06-01)

Statistical modeling based on structured surveys of Australian native possum excreta harboring Mycobacterium ulcerans predicts Buruli ulcer occurrence in humans
by: Koen Vandelannoote, et al.
Published: (2023-04-01)

A severe case of Buruli ulcer disease with pleural effusions.
by: Fred S Sarfo, et al.
Published: (2014-06-01)

Variable Number Tandem Repeat Profiling of Mycobacterium ulcerans Reveals New Genotypes in Buruli Ulcer Endemic Communities in Ghana and Côte d’Ivoire
by: Elizabeth Gyamfi, et al.
Published: (2022-06-01)

High antibody titres induced by protein subunit vaccines using Mycobacterium ulcerans antigens Hsp18 and MUL_3720 with a TLR-2 agonist fail to protect against Buruli ulcer in mice
by: Kirstie M. Mangas, et al.
Published: (2020-08-01)

Therapeutic efficacy of rifalazil (KRM-1648) in a M. ulcerans-induced Buruli ulcer mouse model
by: Hanako Fukano, et al.
Published: (2022-01-01)

Rapid detection of Mycobacterium ulcerans with isothermal recombinase polymerase amplification assay.
by: Michael Frimpong, et al.
Published: (2019-02-01)

Improved protocols for isolation of Mycobacterium ulcerans from clinical samples
by: Bernadette Agbavor, et al.
Published: (2025-03-01)

Infection with Mansonella perstans Nematodes in Buruli Ulcer Patients, Ghana
by: Richard O. Phillips, et al.
Published: (2014-06-01)

IFN-γ and IL-5 whole blood response directed against mycolactone polyketide synthase domains in patients with Mycobacterium ulcerans infection
by: Aloysius D. Loglo, et al.
Published: (2018-07-01)

A human model of Buruli ulcer: Provisional protocol for a Mycobacterium ulcerans controlled human infection study. [version 1; peer review: 1 approved, 2 approved with reservations]
by: Stephen Muhi, et al.
Published: (2024-08-01)

A human model of Buruli ulcer: Provisional protocol for a Mycobacterium ulcerans controlled human infection study. [version 2; peer review: 1 approved, 2 approved with reservations]
by: Stephen Muhi, et al.
Published: (2024-10-01)

Ultra-short-course and intermittent TB47-containing oral regimens produce stable cure against Buruli ulcer in a murine model and prevent the emergence of resistance for Mycobacterium ulcerans
by: Yamin Gao, et al.
Published: (2021-03-01)

Antimicrobial resistant bacteria isolated from Buruli ulcer lesions in Ghana.
by: Nancy Ackam, et al.
Published: (2025-05-01)

Pharmacokinetics of extended-release clarithromycin in patients with Mycobacterium ulcerans infection
by: Sandor-Adrian Klis, et al.
Published: (2024-08-01)

Former Buruli Ulcer Patients' Experiences and Wishes May Serve as a Guide to Further Improve Buruli Ulcer Management.
by: Anita Velink, et al.
Published: (2016-12-01)

Pseudogenomic insights into the evolution of Mycobacterium ulcerans
by: Edwin Sakyi Kyei-Baffour, et al.
Published: (2024-01-01)

Mycobacterium ulcerans Treatment Costs, Australia
by: Christina Drummond, et al.
Published: (2004-06-01)

Translocating Mycobacterium ulcerans: An experimental model.
by: Nassim Hammoudi, et al.
Published: (2020-01-01)

Mycobacterium ulcerans and Mycobacterium marinum: Pathogenesis, Diagnosis and Treatment
by: Loh Teng-Hern Tan, et al.
Published: (2020-09-01)

Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease.
by: Fred Stephen Sarfo, et al.
Published: (2013-01-01)

Mycolactone diffuses into the peripheral blood of Buruli ulcer patients--implications for diagnosis and disease monitoring.
by: Fred S Sarfo, et al.
Published: (2011-07-01)